broker report says sell with valuation 1.50, page-10

my point had been made previously, I am just re-pointing to the concerns

accept pi88 will have similar label warnings, but some key differences

worth a read of the liver phii sae
http://www.progen-pharma.com/prs/progen_...
not much really related to treatment at 160 mg, can't quite work it out but 2 sae related to treatment at 160mg (?) out of 56, and only 4 all up for 160mg+250mg out of 110, not sure about control

and melanoma sae on 250 mg, 5 out of 44 with at least some not likely related to treatment, not sure about expected with no treatment
http://www.progen.com.au/prs/Clinical%20...

Grade 3/4 adverse events were 38% for Nexavar vs. 28% for placebo

see below for not insignificant rates that nexavar patients hair falls out, they get itchy, diarrhea, rash, sick, bleeding, blood pressure

and for 2.5% of them, the old cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo

i think there is a point of difference
given similar activity, which would you rather be on